메뉴 건너뛰기




Volumn 86, Issue 8, 2012, Pages 749-754

Update on the management of chronic kidney disease

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; BICARBONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE PLUS SIMVASTATIN; GADOLINIUM; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; POTASSIUM; SODIUM CHLORIDE; TRIACYLGLYCEROL;

EID: 84868311110     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (8)

References (49)
  • 1
    • 0036176161 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
    • National Kidney Foundation
    • National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
    • (2002) Am J Kidney Dis , vol.39 , Issue.2 SUPPL. 1
  • 2
    • 35848968871 scopus 로고    scopus 로고
    • Prevalence of chronic kidney disease in the United States
    • Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047.
    • (2007) JAMA , vol.298 , Issue.17 , pp. 2038-2047
    • Coresh, J.1    Selvin, E.2    Stevens, L.A.3
  • 3
    • 76749087371 scopus 로고    scopus 로고
    • Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the Kidney Early Evaluation Program (KEEP)
    • Stevens LA, Li S, Wang C, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010;55(3 suppl 2): S23-S33.
    • (2010) Am J Kidney Dis , vol.55 , Issue.3 SUPPL. 2
    • Stevens, L.A.1    Li, S.2    Wang, C.3
  • 4
    • 20544467918 scopus 로고    scopus 로고
    • Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999
    • Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489-495.
    • (2005) J Am Soc Nephrol , vol.16 , Issue.2 , pp. 489-495
    • Foley, R.N.1    Murray, A.M.2    Li, S.3
  • 5
    • 40449090625 scopus 로고    scopus 로고
    • United States Renal Data System, Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U.S. Department of Health and Human Services
    • United States Renal Data System. 2007 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U.S. Department of Health and Human Services; 2007.
    • (2007) 2007 Annual Data Report
  • 6
    • 33845760213 scopus 로고    scopus 로고
    • KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease
    • Kidney Disease Outcomes Quality Initiative (KDOQI)
    • Kidney Disease Outcomes Quality Initiative (KDOQI). KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 suppl 2): S12-S154.
    • (2007) Am J Kidney Dis , vol.49 , Issue.2 SUPPL. 2
  • 7
    • 78651338445 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2011
    • American Diabetes Association
    • American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(suppl 1):S11-S61.
    • (2011) Diabetes Care , vol.34 , Issue.SUPPL. 1
  • 8
    • 58149301489 scopus 로고    scopus 로고
    • Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
    • American Diabetes Association; American College of Cardiology Foundation; American Heart Association
    • Skyler JS, Bergenstal R, Bonow RO, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009; 53(3):298-304.
    • (2009) J Am Coll Cardiol , vol.53 , Issue.3 , pp. 298-304
    • Skyler, J.S.1    Bergenstal, R.2    Bonow, R.O.3
  • 9
    • 77955585592 scopus 로고    scopus 로고
    • Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial
    • ACCORD trial group, published correction appears in Lancet. 2010;376(9751):1466
    • Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial [published correction appears in Lancet. 2010;376(9751):1466]. Lancet. 2010;376(9739):419-430.
    • (2010) Lancet , vol.376 , Issue.9739 , pp. 419-430
    • Ismail-Beigi, F.1    Craven, T.2    Banerji, M.A.3
  • 10
    • 45149133036 scopus 로고    scopus 로고
    • Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    • ADVANCE Collaborative Group
    • Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
    • (2008) N Engl J Med , vol.358 , Issue.24 , pp. 2560-2572
    • Patel, A.1    Macmahon, S.2    Chalmers, J.3
  • 11
    • 0037968349 scopus 로고    scopus 로고
    • Guidelines for improving the care of the older person with diabetes mellitus
    • California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes, guidelines
    • Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(5 suppl guidelines):S265-S280.
    • (2003) J Am Geriatr Soc , vol.51 , Issue.5 SUPPL
    • Brown, A.F.1    Mangione, C.M.2    Saliba, D.3    Sarkisian, C.A.4
  • 12
    • 46449117004 scopus 로고    scopus 로고
    • The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: A decision analysis
    • Huang ES, Zhang Q, Gandra N, Chin MH, Meltzer DO. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med. 2008;149(1):11-19.
    • (2008) Ann Intern Med , vol.149 , Issue.1 , pp. 11-19
    • Huang, E.S.1    Zhang, Q.2    Gandra, N.3    Chin, M.H.4    Meltzer, D.O.5
  • 13
    • 75849147039 scopus 로고    scopus 로고
    • Relation between kidney function, proteinuria, and adverse outcomes
    • Alberta Kidney Disease Network
    • Hemmelgarn BR, Manns BJ, Lloyd A, et al.; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423-429.
    • (2010) JAMA , vol.303 , Issue.5 , pp. 423-429
    • Hemmelgarn, B.R.1    Manns, B.J.2    Lloyd, A.3
  • 14
    • 77953291706 scopus 로고    scopus 로고
    • Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis
    • Chronic Kidney Disease Prognosis Consortium
    • Matsushita K, van der Velde M, Astor BC, et al.; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081.
    • (2010) Lancet , vol.375 , Issue.9731 , pp. 2073-2081
    • Matsushita, K.1    van der Velde, M.2    Astor, B.C.3
  • 15
    • 3042819708 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease
    • Kidney Disease Outcomes Quality Initiative (K/DOQI)
    • Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 suppl 1):S1-S290.
    • (2004) Am J Kidney Dis , vol.43 , Issue.5 SUPPL. 1
  • 16
    • 38049139424 scopus 로고    scopus 로고
    • Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease
    • Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48.
    • (2008) Ann Intern Med , vol.148 , Issue.1 , pp. 30-48
    • Kunz, R.1    Friedrich, C.2    Wolbers, M.3    Mann, J.F.4
  • 17
    • 0027517659 scopus 로고
    • The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
    • published correction appars in N Engl J Med. 1993;330(2):152, The Collaborative Study Group
    • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [published correction appars in N Engl J Med. 1993;330(2):152]. N Engl J Med. 1993;329(20):1456-1462.
    • (1993) N Engl J Med , vol.329 , Issue.20 , pp. 1456-1462
    • Lewis, E.J.1    Hunsicker, L.G.2    Bain, R.P.3    Rohde, R.D.4
  • 18
    • 0035922447 scopus 로고    scopus 로고
    • Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    • Collaborative Study Group
    • Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
    • (2001) N Engl J Med , vol.345 , Issue.12 , pp. 851-860
    • Lewis, E.J.1    Hunsicker, L.G.2    Clarke, W.R.3
  • 19
    • 0035902622 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data
    • published correction appears in Ann Intern Med. 2002;137(4):299
    • Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data [published correction appears in Ann Intern Med. 2002;137(4):299]. Ann Intern Med. 2001;135(2):73-87.
    • (2001) Ann Intern Med , vol.135 , Issue.2 , pp. 73-87
    • Jafar, T.H.1    Schmid, C.H.2    Landa, M.3
  • 20
    • 66149192531 scopus 로고    scopus 로고
    • Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: Is the evidence base relevant to older adults?
    • O'Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med. 2009;150(10):717-724.
    • (2009) Ann Intern Med , vol.150 , Issue.10 , pp. 717-724
    • O'Hare, A.M.1    Kaufman, J.S.2    Covinsky, K.E.3    Landefeld, C.S.4    McFarland, L.V.5    Larson, E.B.6
  • 21
    • 0035203597 scopus 로고    scopus 로고
    • ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy
    • Gruppo Italiano di Studi Epidemiologici in Nefrologia
    • Ruggenenti P, Perna A, Remuzzi G; Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol. 2001;12(12):2832-2837.
    • (2001) J Am Soc Nephrol , vol.12 , Issue.12 , pp. 2832-2837
    • Ruggenenti, P.1    Perna, A.2    Remuzzi, G.3
  • 22
    • 30444452987 scopus 로고    scopus 로고
    • Efficacy and safety of benazepril for advanced chronic renal insufficiency
    • Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2): 131-140.
    • (2006) N Engl J Med , vol.354 , Issue.2 , pp. 131-140
    • Hou, F.F.1    Zhang, X.2    Zhang, G.H.3
  • 23
    • 0034627208 scopus 로고    scopus 로고
    • Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
    • Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-1444.
    • (2000) BMJ , vol.321 , Issue.7274 , pp. 1440-1444
    • Mogensen, C.E.1    Neldam, S.2    Tikkanen, I.3
  • 24
    • 49149087718 scopus 로고    scopus 로고
    • Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
    • ONTARGET investigators
    • Mann JF, Schmieder RE, McQueen M, et al.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553.
    • (2008) Lancet , vol.372 , Issue.9638 , pp. 547-553
    • Mann, J.F.1    Schmieder, R.E.2    McQueen, M.3
  • 25
    • 0038460302 scopus 로고    scopus 로고
    • The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report
    • National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee, published correction appears in JAMA. 2003;290(2):197
    • Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290(2):197]. JAMA. 2003;289(19):2560-2572.
    • (2003) JAMA , vol.289 , Issue.19 , pp. 2560-2572
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 27
    • 79955375480 scopus 로고    scopus 로고
    • Systematic review: Blood pressure target in chronic kidney disease and proteinuria as an effect modifier
    • Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154(8):541-548.
    • (2011) Ann Intern Med , vol.154 , Issue.8 , pp. 541-548
    • Upadhyay, A.1    Earley, A.2    Haynes, S.M.3    Uhlig, K.4
  • 28
    • 67649426365 scopus 로고    scopus 로고
    • HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
    • Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;(2):CD007784.
    • (2009) Cochrane Database Syst Rev , Issue.2
    • Navaneethan, S.D.1    Pansini, F.2    Perkovic, V.3
  • 29
    • 79959746706 scopus 로고    scopus 로고
    • The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial
    • SHARP Investigators
    • Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192.
    • (2011) Lancet , vol.377 , Issue.9784 , pp. 2181-2192
    • Baigent, C.1    Landray, M.J.2    Reith, C.3
  • 30
    • 0037379751 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease
    • Kidney Disease Outcomes Quality Initiative (K/DOQI) Group
    • Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(4 suppl 3):I-IV, S1-S91.
    • (2003) Am J Kidney Dis , vol.41 , Issue.4 SUPPL. 3
  • 31
    • 0035873251 scopus 로고    scopus 로고
    • Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial
    • Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134(10):931-940.
    • (2001) Ann Intern Med , vol.134 , Issue.10 , pp. 931-940
    • Hunt, D.1    Young, P.2    Simes, J.3
  • 32
    • 77958577146 scopus 로고    scopus 로고
    • Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds
    • Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing. 2010;39(6):674-680.
    • (2010) Age Ageing , vol.39 , Issue.6 , pp. 674-680
    • Petersen, L.K.1    Christensen, K.2    Kragstrup, J.3
  • 33
    • 32944454579 scopus 로고    scopus 로고
    • Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients
    • Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2005;(3):CD003266.
    • (2005) Cochrane Database Syst Rev , Issue.3
    • Cody, J.1    Daly, C.2    Campbell, M.3
  • 34
    • 34548046760 scopus 로고    scopus 로고
    • KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target
    • Kidney Disease Outcomes Quality Initiative (KDOQI)
    • Kidney Disease Outcomes Quality Initiative (KDOQI). KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530.
    • (2007) Am J Kidney Dis , vol.50 , Issue.3 , pp. 471-530
  • 36
    • 33750983605 scopus 로고    scopus 로고
    • Correction of anemia with epoetin alfa in chronic kidney disease
    • CHOIR Investigators
    • Singh AK, Szczech L, Tang KL, et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
    • (2006) N Engl J Med , vol.355 , Issue.20 , pp. 2085-2098
    • Singh, A.K.1    Szczech, L.2    Tang, K.L.3
  • 37
    • 33751002326 scopus 로고    scopus 로고
    • Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    • CREATE Investigators
    • Drüeke TB, Locatelli F, Clyne N, et al.; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084.
    • (2006) N Engl J Med , vol.355 , Issue.20 , pp. 2071-2084
    • Drüeke, T.B.1    Locatelli, F.2    Clyne, N.3
  • 38
    • 70949108082 scopus 로고    scopus 로고
    • A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
    • TREAT Investigators
    • Pfeffer MA, Burdmann EA, Chen CY, et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032.
    • (2009) N Engl J Med , vol.361 , Issue.21 , pp. 2019-2032
    • Pfeffer, M.A.1    Burdmann, E.A.2    Chen, C.Y.3
  • 39
    • 84455194972 scopus 로고    scopus 로고
    • FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythopoiesis-stimulating Agents (ESAs) In Chronic Kidney Disease
    • U.S. Food and Drug Administration, Accessed September 1, 2011
    • U.S. Food and Drug Administration. FDA drug safety communication: Modified dosing recommendations to improve the safe use of erythopoiesis-stimulating agents (ESAs) in chronic kidney disease. http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Accessed September 1, 2011.
  • 40
    • 33745283670 scopus 로고    scopus 로고
    • Prophylaxis strategi es for contrast-induced nephropathy
    • Alberta Kidney Disease Network
    • Pannu N, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Prophylaxis strategi es for contrast-induced nephropathy. JAMA. 2006; 295(23):2765-2779.
    • (2006) JAMA , vol.295 , Issue.23 , pp. 2765-2779
    • Pannu, N.1    Wiebe, N.2    Tonelli, M.3
  • 41
    • 0030661687 scopus 로고    scopus 로고
    • Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality
    • McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368-375.
    • (1997) Am J Med , vol.103 , Issue.5 , pp. 368-375
    • McCullough, P.A.1    Wolyn, R.2    Rocher, L.L.3    Levin, R.N.4    O'Neill, W.W.5
  • 42
    • 4644296839 scopus 로고    scopus 로고
    • A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation
    • Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393-1399.
    • (2004) J Am Coll Cardiol , vol.44 , Issue.7 , pp. 1393-1399
    • Mehran, R.1    Aymong, E.D.2    Nikolsky, E.3
  • 43
    • 33747890431 scopus 로고    scopus 로고
    • Risk prediction of contrast-induced nephropathy
    • CIN Consensus Working Panel
    • McCullough PA, Adam A, Becker CR, et al.; CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):27K-36K.
    • (2006) Am J Cardiol , vol.98 , Issue.6 A
    • McCullough, P.A.1    Adam, A.2    Becker, C.R.3
  • 44
    • 31344440606 scopus 로고    scopus 로고
    • Clinical practice. Preventing nephropathy induced by contrast medium
    • Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354(4):379-386.
    • (2006) N Engl J Med , vol.354 , Issue.4 , pp. 379-386
    • Barrett, B.J.1    Parfrey, P.S.2
  • 45
    • 68749089747 scopus 로고    scopus 로고
    • High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy
    • Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med. 2009;122(9):874.e9-e15.
    • (2009) Am J Med , vol.122 , Issue.9
    • Trivedi, H.1    Daram, S.2    Szabo, A.3    Bartorelli, A.L.4    Marenzi, G.5
  • 46
    • 78049252959 scopus 로고    scopus 로고
    • Strategies for the prevention of contrast-induced acute kidney injury
    • Weisbord SD, Palevsky PM. Strategies for the prevention of contrast-induced acute kidney injury. Curr Opin Nephrol Hypertens. 2010;19(6):539-549.
    • (2010) Curr Opin Nephrol Hypertens , vol.19 , Issue.6 , pp. 539-549
    • Weisbord, S.D.1    Palevsky, P.M.2
  • 47
    • 66849141052 scopus 로고    scopus 로고
    • Current status of gadolinium toxicity in patients with kidney disease
    • published correction appears in Clin J Am Soc Nephrol. 2009;4(4):866
    • Perazella MA. Current status of gadolinium toxicity in patients with kidney disease [published correction appears in Clin J Am Soc Nephrol. 2009;4(4):866]. Clin J Am Soc Nephrol. 2009;4(2):461-469.
    • (2009) Clin J Am Soc Nephrol , vol.4 , Issue.2 , pp. 461-469
    • Perazella, M.A.1
  • 48
    • 73649090430 scopus 로고    scopus 로고
    • NSF prevention in clinical practice: Summary of recommendations and guidelines in the United States, Canada, and Europe
    • Leiner T, Kucharczyk W. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe. J Magn Reson Imaging. 2009;30(6):1357-1363.
    • (2009) J Magn Reson Imaging , vol.30 , Issue.6 , pp. 1357-1363
    • Leiner, T.1    Kucharczyk, W.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.